Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Rating) – Investment analysts at SVB Leerink lowered their Q1 2023 earnings per share estimates for Crinetics Pharmaceuticals in a research report issued to clients and investors on Wednesday, March 1st. SVB Leerink analyst J. Schwartz now forecasts that the company will post earnings of ($0.83) per share for […]